Intermediate-term outcomes of pars plana tube insertion of Aurolab aqueous drainage implant for refractory glaucoma

Purpose To report the safety and efficacy of parsplana tube insertion of Aurolab aqueous drainage implant(AADI) in patients with refractory glaucoma. Methods Charts of patients with refractory glaucoma who underwent AADI via the parsplana route between June 2014 and June 2018with a minimum follow-up of 6 months were retrospectively reviewed. Success was defined as complete when the intraocular pressure (IOP) was >= 5 and18 mmHg or IOP reduction was >= 30%from baseline without antiglaucoma medication (AGM) andas qualified if requiring additional AGMs. Results The study included 63 eyes of 63 patients with a mean age of 36.1 +/- 20.6 years and a mean follow-up of 19.7 +/- 15.7 months. Glaucoma postvitreoretinal surgery was the the most common aetiology (22 eyes, 35%). The mean 10P reduced from 36.6 +/- 10.7 mmHg to15.7 +/- 8.2 (57.1%), 15.02 +/- 7.3 (60%) and 17.2 +/- 8.5 mmHg (53%)at 6 months and 1 and 2 years, respectively. Kaplan-Meier estimates showed that the cumulative probabilities of failure were 8% (95% C14.3% to 22.4%) at 6 months, 23% (95%CI12.8% to 38.6%) at 1 year, 30% (95%C117.4% to 45.9%) at 18 months and 47% (95% CI13.4% to 64.9%) at the 2 years time points.Vitreous blocking tube tip was noted up to 8% of eyes on follow-up. Conclusion Pars plana AADI insertion is a useful procedure for the control of 10P in patients with refractory glaucoma.